Assadiasl Sara, Mooney Nuala, Mohebbi Bahareh, Fatahi Yousef, Soleimanifar Narjes
Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Human Immunology and Immunopathology, Inserm UMR 976, Paris, France.
J Transplant. 2020 Apr 25;2020:9012980. doi: 10.1155/2020/9012980. eCollection 2020.
Sirtuin 1, a member of sirtuin family of histone deacetylase enzymes, has been implicated in a variety of physiologic and pathologic events, including energy metabolism, cell survival, and age-related alterations. In view of the anti-inflammatory properties of sirtuin 1 along with its protective role in ischemia reperfusion injury, it might be considered as contributing to the promotion of transplantation outcome. However, the potential ability of sirtuin 1 to induce malignancies raises some concerns about its overexpression in clinic. Moreover, despite the findings of sirtuin 1 implication in thymic tolerance induction and T regulatory (Treg) cells survival, there is also evidence for its involvement in Treg suppression and in T helper 17 cells differentiation. The identification of sirtuin 1 natural and synthetic activators leads to the proposal of sirtuin 1 as an eligible target for clinical interventions in transplantation. All positive and negative consequences of sirtuin 1 overactivation/overexpression in the allograft should therefore be studied thoroughly. Herein, we summarize previous findings concerning direct and indirect influences of sirtuin 1 manipulation on transplantation.
沉默调节蛋白1是组蛋白脱乙酰酶沉默调节蛋白家族的成员之一，与多种生理和病理过程有关，包括能量代谢、细胞存活以及与年龄相关的改变。鉴于沉默调节蛋白1的抗炎特性及其在缺血再灌注损伤中的保护作用，它可能有助于提高移植成功率。然而，沉默调节蛋白1诱导恶性肿瘤的潜在能力引发了人们对其在临床上过度表达的担忧。此外，尽管有研究发现沉默调节蛋白1参与胸腺耐受诱导和调节性T（Treg）细胞存活，但也有证据表明它参与Treg抑制和辅助性T17细胞分化。沉默调节蛋白1天然和合成激活剂的发现，使得沉默调节蛋白1成为移植临床干预的一个合适靶点。因此，需要全面研究沉默调节蛋白1在同种异体移植物中过度激活/过度表达的所有正面和负面后果。在此，我们总结了先前关于沉默调节蛋白1调控对移植的直接和间接影响的研究结果。
